期刊文献+

榄香烯聚氰基丙烯酸正丁酯纳米粒子在Wistar大鼠脑组织中的靶向分布 被引量:3

下载PDF
导出
摘要 目的观察榄香烯聚氰基丙烯酸正丁酯纳米微粒(Gd-PBCA-NP)在Wistar大鼠脑组织中的靶向分布。方法 36只清洁Wistar大鼠,选择阴离子乳化聚合法,对定量Gd-DTPA与Dextran-70进行精密称取,通过Malvern-3000HS激光粒度分析仪对Gd-PBCA-NP的粒径及实际分布进行测定。采用随机数字的方式将36只Wistar大鼠平均分为PBCA-NP组、Gd-DTPA对照组及Gd-PBCA-NP组,选择头部线圈行磁共振成像(MRI)扫描,并行横断面与冠状面扫描。结果通过透射电镜对Gd-PBCA-NP进行观察发现呈类圆形,而且大小比较均匀,具有完整、平滑的表面,粒子间未粘连,其核-壳结构较为显著,Gd-DTPA静脉注射后5 min,相比于平行扫描,脑组织强化35.0%,注射15 min后,大鼠脑组织强化为48.5%,0.5 h后,大鼠脑组织信号强度与平扫前水平相同。行Gd-PBCA-NP的静脉注射后5 min,大鼠脑组织信号强度为3.5%,注射15 min后,大鼠脑组织强化为22.6%,0.5 h后,大鼠脑组织信号强度持续升高,强化程度在36.2%,并在注射1 h后达到最峰值,即56.5%,注射2 h开始降低,相比于平扫,依旧比较高。结论 Gd-DTPA-NP的缓释特点极为理想,可以实现靶向脑组织成像。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2016年第14期3400-3401,共2页 Chinese Journal of Gerontology
  • 相关文献

参考文献6

  • 1Tian XH,Lin XN,Wei F,et al.Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles[J].Int JNanomed,2011;6(6):445-52.
  • 2黄乐松,王春霞,陈志良,徐越,王羽伦,钟延松,刘园.吉西他滨聚氰基丙烯酸正丁酯纳米粒在小鼠脑内的靶向分布[J].中国医院药学杂志,2008,28(16):1332-1336. 被引量:4
  • 3Zhang XN,Tang LH,Gong JH,et al.Alternative albendazole polybutylcyanoacrylate nanoparticles preparation,pharmaceutical properties and tissue distribution in rats[J].Lett Drug Des Dis,2006;3(4):275-80.
  • 4吕国士,许乙凯.新型MR特异性对比剂Gd-聚氰基丙烯酸正丁酯纳米微粒的合成及其肝脏靶向性(英文)[J].中国组织工程研究与临床康复,2009,13(8):1569-1572. 被引量:1
  • 5Rong T,Mengmeng N,Jihui Z,et al.Preparation of vincristine sulfateloaded poly(butylcyanoacrylate)nanoparticles modified with pluronic F127 and evaluation of their lymphatic tissue targeting[J].J Drug Target,2014;22(6):509-17.
  • 6Bagad M,Khan ZA.Poly(n-butylcyanoacrylate)nanoparticles for oral delivery of quercetin:preparation,characterization and pharmacokinetics and biodistribution studies in Wistar rats[J].Int J Nanomed,2015;10:3921-35.

二级参考文献21

  • 1张彩霞,林能明.吉西他滨药代动力学研究进展[J].肿瘤学杂志,2004,10(4):271-274. 被引量:10
  • 2林能明,曾苏,马胜林,范云,钟海均,方罗.RP-HPLC法测定人体血浆中吉西他滨的浓度[J].药物分析杂志,2004,24(5):453-456. 被引量:7
  • 3Friese A, Seiller E, Quack G, et al. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm. 2000;49(2):103-109.
  • 4Kreuter J. Nanoparticulate systems for brain delivery Of drugs. Adv Drug Deliv Rev. 2001 ;47(1):65-81.
  • 5The Ministry of Science and Technology of the People's Republic of China. Regulations for the Administration of Affairs Concerning Experimental Animals. 1988-10-31.
  • 6Couvreur P, Kante B, Roland M, et al. Polycyanoacrylate nanocapsules as potential lysosomotropic carriers: preparation, morphological and sorptive properties. J Pharm Pharmacol. 1979;31 (5):331-332.
  • 7Vauthier C, Dubernet C, Fattal E, et al. Poly(aikylcyanoacrylates) as biodegradable materials for biomedical applications. Adv Drug Deliv Rev. 2003;55(4):519-548.
  • 8Ghanem GE, Joubran C, Arnould R, et al. Labelled polycyanoacrylate nanoparticles for human in vivo use. Appl Radiat Isot. 1993;44(9):1219-1224.
  • 9Shikata F, Tokumitsu H, Ichikawa H, et al. In vitro cellular accumulation of gadolinium incorporated into chitosan nanoparticles designed for neutron-capture therapy of cancer. Eur J Pharm Biopharm. 2002;53(1):57-63.
  • 10Verdun C, Brasseur F, Vranckx H, et al. Tissue distribution of doxorubicin associated with polyisohexylcyanoacrylate nanoparticles. Cancer Chemother Pharmacoi.1990;26(1 ):13-18.

共引文献3

同被引文献36

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部